New research has found a link between semaglutide and improved brain health in people with type 2 diabetes.
The hottest drug on the market might also be an unexpected brain booster. In a study published this month, scientists found evidence that semaglutide—the active ingredient in Ozempic and Wegovy—can have possible benefits for people’s cognition as well as helpSemaglutide is part of a drug class that mimics naturally occurring GLP-1, an important hormone that helps regulate our blood sugar and hunger, among other functions.
Clinical trials have shown that semaglutide can prevent heart and kidney disease in obese people vulnerable to it, for instance, while more speculative research has even suggested that GLP-1 drugs can blunt a person’s. Scientists from the UK’s National Institute for Health Research Oxford Health Biomedical Research Center and the Medical Research Council conducted this latest study, deciding to look at semaglutide’s possible effects on the brain.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic, Weight Loss Drugs, and Vision Loss: What to Know About Recent StudyYou may have heard of type 1 and type 2, but there are many more types of diabetes you should know about. Here are six types, from gestational to monogenic.
Read more »
Ozempic and Mounjaro may also lower your risk of obesity-linked cancerA study found another potential benefit of the weight loss drugs: lowered risk of chronic conditions.
Read more »
House committee passes bill that would allow Medicare to cover weight loss drugsBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Non-Diabetic Use Of GLP-1 Drugs Like Ozempic For Weight Loss Affecting Retail Sizing CurvesI've been a journalist for 30 years, as a senior editor at W magazine, and for the last 17 years, covering retail and real estate as a senior editor at WWD. I write about luxury boutiques, independent retailers, department stores, mass chains, and digitally native brands, and the force that's redefining the way we shop – Amazon.
Read more »
Next Gen Weight Loss Drugs Are Coming for Ozempic’s ThroneDozens of obesity and diabetes treatments are in the pipeline, some of which may help people lose even more weight than existing drugs like semaglutide.
Read more »
Cosmetic Surgery Trends: Weight Loss Drugs Drove Spike In Fillers And Facelifts Last Year, Report SuggestsArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »